Annual report pursuant to Section 13 and 15(d)

Combined and Consolidated Statements of Operations (Parenthetical)

v3.20.2
Combined and Consolidated Statements of Operations (Parenthetical) - USD ($)
$ in Thousands
12 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Research and Development Expense [Member]    
Share-based compensation expense $ 3,130 $ 1,193
Research and Development Expense [Member] | Roivant Sciences Ltd. (RSL) [Member]    
Costs allocated from related party 159 3,582
General and Administrative Expense [Member]    
Share-based compensation expense 3,833 115
General and Administrative Expense [Member] | Roivant Sciences Ltd. (RSL) [Member]    
Costs allocated from related party $ 1,381 $ 1,180